BCL2L1 and lung carcinoma: Recently, a study in lung cancer cell lines and PDX models showed that combining BGJ398 with either the Bcl‐XL inhibitor A1331852 or the Mcl‐1 inhibitor S63845 led to a small survival benefit and that only triple inhibition resulted in tumour regression (Weeden et al., 2018).